IQR Group Pty Ltd - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

onivyde

servier laboratories nz ltd - irinotecan hydrochloride trihydrate 5 mg/ml (equiv 4.3 mg/ml irinotecan (anhydrous free base)); - concentrate for infusion - 43 mg/10ml - active: irinotecan hydrochloride trihydrate 5 mg/ml (equiv 4.3 mg/ml irinotecan (anhydrous free base)) excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine cholesterol hepes n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium chloride sucrosofate water for injection - treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil and folinic acid (leucovorin) in adult patients who have been previously treated with gemcitabine

New Zealand - English - Medsafe (Medicines Safety Authority)

alprolix

pharmacy retailing (nz) ltd t/a healthcare logistics - eftrenonacog alfa 4000 [iu]; - powder for infusion - 4000 iu - active: eftrenonacog alfa 4000 [iu] excipient: histidine hydrochloric acid mannitol polysorbate 20 sucrose sodium chloride water for injection - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Israel - English - Ministry of Health

decitabine - trima 50 mgvial

trima israel pharmaceutical products maabarot ltd - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg - decitabine - decitabine trima is indicated for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2 and high-risk international prognostic scoring system groups. decitabine trima is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy